Alnylam Pharmaceuticals (ALNY) Stock Highlights

248.79 | +6.2%

2024-11-20 23:49:08

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylams cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Statistics

Range Today

234.44 249.1

Volume Today 1.03M

Range 1 Year

141.98 304.39

Volume 1 Year 212.66M

Range 3 Year

117.58 304.39

Volume 3 Year 614.01M

Range 10 Year

31.38 304.39

Volume 10 Year 2.15B

Highlights

Market Capitalization 35.78B (large)

Floating Shares 128.44M

Current Price 248.79

Price To Earnings -104.68

Price To Revenue 16.73

Price To Book 1.11K

Earnings Per Share -2.61

Payout Ratio 0%

Performance

Latest +6.2%

1 Month -15.47%

3 Months -9.5%

6 Months +66.64%

1 Year +51.87%

3 Years +31.64%

5 Years +153.92%

10 Years +180.23%

Benchmarks

Market Capitalization

6 / 368

Gross Profits

14 / 278

Total Revenue

13 / 300

Total Rank

96 / 368

Free Cashflow

167 / 352

Performance 5 years

57 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.